Real-World Phenotypic Profiles and Longitudinal Lung Function Outcomes in Severe Asthma Treated with Biologic Therapies
Journal of Personalized Medicine · 03.07.2026 · 16 (7) · 362
DOI: 10.3390/jpm16070362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 03.07.2026. Verfasst von Ourania S Kotsiou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Human Pathophysiology, Department of Nursing, University of Thessaly, Gaiopolis, 41500 Larissa, Greece. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Biologic therapies have transformed severe asthma management, but real-world evidence comparing phenotypes, lung function trajectories, and persistence across biologic classes remains limited.
Objective
To characterize a real-world cohort of biologic-treated severe asthma patients, focusing on baseline phenotypes, longitudinal post-bronchodilator spirometry (including a spirometric surrogate suggestive of small airways involvement), and discontinuation/switching patterns.
Methods
In this retrospective observational study at a tertiary referral center, adults with severe asthma treated with benralizumab, mepolizumab, omalizumab, or tezepelumab were included. Demographic, clinical, biomarker, and functional data were collected at baseline and follow-up. Post-bronchodilator FEV1 and FEF25–75 (% predicted) were assessed at baseline, 6 months, 12 months, and 24–36 months when available. Longitudinal outcomes were analyzed using multivariable linear mixed-effects models; discontinuation and switching were recorded.
Results
Eighty-seven patients were included (benralizumab n = 13, omalizumab n = 10, mepolizumab n = 30, tezepelumab n = 34), representing 10.9% of the clinic’s population. Most had long-standing disease, elevated body mass index, and a T2-high profile. Baseline characteristics were generally similar across groups, with expected differences in total IgE (p = 0.007) and blood eosinophils (p < 0.001). The primary endpoint (FEV1 % predicted change from baseline to 12 months) showed adjusted mean changes of +12.46 (95% CI +1.63 to +19.29; p = 0.020) with benralizumab, +15.82 (+8.35 to +23.64; p < 0.001) with mepolizumab, +16.65 (+1.58 to +31.71; p < 0.001) with omalizumab, and +15.69 (+6.52 to +24.87; p = 0.030) with tezepelumab; trajectories differed by biologic class (time × biologic p = 0.019). Although the interaction term indicated heterogeneous temporal patterns, these adjusted findings should be interpreted as associative in the context of biomarker-driven treatment selection and not as evidence of comparative superiority of any biologic class. Discontinuation occurred in 15/87 (17.2%), with switching most commonly due to inadequate control.
Conclusions
Real-world severe asthma patients demonstrate heterogeneous phenotypes and spirometric trajectories on biologics. Integrating biomarkers with longitudinal lung function monitoring, including small-airway spirometric surrogates, supports individualized management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Human Pathophysiology, Department of Nursing, University of Thessaly, Gaiopolis, 41500 Larissa, Greece.
- Department of Respiratory Medicine, University of Thessaly, Biopolis, 41110 Larissa, Greece.
ORCID-Profile: Ourania S Kotsiou, Georgios I Barkas, Konstantinos I Gourgoulianis, Zoe Daniil
Zitieren
APA
Kotsiou, O. S., Barkas, G. I., Gourgoulianis, K. I., & Daniil, Z. (2026). Real-World Phenotypic Profiles and Longitudinal Lung Function Outcomes in Severe Asthma Treated with Biologic Therapies. Journal of Personalized Medicine, 16(7), 362. https://doi.org/10.3390/jpm16070362
Vancouver
Kotsiou OS, Barkas GI, Gourgoulianis KI, Daniil Z. Real-World Phenotypic Profiles and Longitudinal Lung Function Outcomes in Severe Asthma Treated with Biologic Therapies. Journal of Personalized Medicine. 2026;16(7):362. doi:10.3390/jpm16070362
BibTeX
@article{Kotsiou2026,
author = {Kotsiou, Ourania S and Barkas, Georgios I and Gourgoulianis, Konstantinos I and Daniil, Zoe},
title = {Real-World Phenotypic Profiles and Longitudinal Lung Function Outcomes in Severe Asthma Treated with Biologic Therapies},
journal = {Journal of Personalized Medicine},
year = {2026},
volume = {16},
number = {7},
pages = {362},
doi = {10.3390/jpm16070362}
}
EUVIMED